Validity And Responsiveness Of The Bristol Rheumatoid Arthritis Fatigue Multidimensional Questionnaire (BRAF-MDQ) In A Randomized Controlled Clinical Trial

Abstract

Objectives: In COPD, disturbed sleep is related to exacerbation frequency, poor quality of life and early mortality. We developed the Manchester Sleep Symptoms Index (MSSI) to assess night-time symptoms and disturbed sleep in COPD. MethOds: Identification of potential items was guided by interviews and focus groups involving COPD patients and age-matched controls. Hierarchical methods and Rasch analysis informed item deletion and development of a unidimensional scale. Internal consistency and test-retest reliability were assessed. Concurrent validity was examined using Pearson's correlation with the St George's Respiratory Questionnaire (SGRQ), modified MRC Dyspnoea Scale, FACIT fatigue scale, MOS Sleep Scale, HADS Anxiety and Depression scores. Results: Qualitative data from 36 patients with COPD and 10 age-matched controls informed an initial list of 22 items. The cross-sectional study included 203 COPD patients (GOLD: I: 14% II: 41% III: 25% IV: 7%; male: 63%, mean age: 64.7; SD: 7.5 years) and 50 non-COPD controls. 12 items were removed during hierarchical methods and a further two following Rasch analysis. The final MSSI contains 8 sleep-related items that are specific to COPD patients: breathlessness, chest tightness, cough and sputum production. The index has good internal consistency (Cronbach's alpha 0.87), test-retest repeatability (intra-class coefficient 0.77) and validity. Total MSSI scores significantly correlated with the SGRQ (r= 0.64); MRC Dyspnoea scale (r= 0.46), FACIT-F (r= -0.61); MOS problems index 2: (r= 0.62); MOS Sleep adequacy (r= 0.40); MOS Sleep disturbance (r= 0.53) HADS anxiety (r= 0.54) and depression (0.48). There was good overall fit to the Rasch model (Chi-squared: 29.2 df: 16 p= 003.) and distribution of item scores. cOnclusiOns: The MSSI is a reliable, valid, uni-dimensional self-reported outcome measure of sleep and night-time symptoms for people with COPD. It is simple and quick to use making it suitable for research and practice. Further work is needed to determine the minimal clinical important difference and cross cultural validity.Objectives: Individuals with BrCa have high decisional conflict with respect to treatment decisions. GEP of tumours informs risk prediction, potentially affecting decisions about adjuvant chemotherapy in early BrCa, where only 15% will experience recurrence. We aimed to examine whether GEP reduces decisional conflict in

Fatigue in rheumatoid arthritis patients: The status, independent risk factors, and consistency of multiple scales

“…Fatigue of RA patients and healthy controls were evaluated based on BRAF-MDQ and BFI-C after enrollment. 18,23 BRAF-MDQ contains 20 items and encompasses a global score (Score 0-70) as well as physical (Score 0-22), living (Score 0-21), cognitive (Score 0-15), and emotional (Score 0-12) subdomain scores. The higher score indicates a more severe fatigue level.…”

Measures of Fatigue in Patients With Rheumatic Diseases: A Critical Review

“…Many studies use the 14‐item CFQ draft (score range 0‐42), giving an average global fatigue score in 120 patients with systemic lupus erythematosus (SLE) of 22 (interquartile range [IQR] 16‐28) . Using the 14‐item CFQ draft with an aggregated fifth response option (score range 0‐56), the overall median fatigue in 51 patients with primary Sjögren’s syndrome (SS) was 37 (IQR ) vs. 28 (IQR ) in 51 control subjects ( P < 0.01) .…”

Multimorbidity and Fatigue in Rheumatoid Arthritis: A Cross-Sectional Study of a Population-Based Cohort

“…The Bristol Rheumatoid Arthritis Fatigue Multidimensional Questionnaire (BRAF-MDQ) was used to comprehensively assess fatigue and related health domains [26][27][28][29][30]. This 20-item questionnaire encompasses a total score (range, 0-70) as well as physical (range, 0-22), living with fatigue (range, 0-21), cognitive (range, 0-15), and emotional (range, 0-12) subdomain scores.…”

“…A salient attribute of this scale is that it was developed in collaboration with patient research partners [31]. The BRAF-MDQ has been shown to be valid, reliable, and sensitive to change for use in RA clinical research and practice [27,28].…”